These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 21163254

  • 1. Cis-4-methylsphingosine is a sphingosine-1-phosphate receptor modulator.
    Ter Braak M, Claas RF, Hegen B, Labocha S, Ferreirós N, Pfeilschifter J, Huwiler A, van Echten-Deckert G, Meyer Zu Heringdorf D.
    Biochem Pharmacol; 2011 Mar 01; 81(5):617-25. PubMed ID: 21163254
    [Abstract] [Full Text] [Related]

  • 2. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
    Lee CW, Choi JW, Chun J.
    Arch Pharm Res; 2010 Oct 01; 33(10):1567-74. PubMed ID: 21052934
    [Abstract] [Full Text] [Related]

  • 3. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A.
    Neurology; 2011 Feb 22; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [Abstract] [Full Text] [Related]

  • 4. New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets.
    Huwiler A, Pfeilschifter J.
    Biochem Pharmacol; 2008 May 15; 75(10):1893-900. PubMed ID: 18321471
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Sphingosine-1-phosphate-induced airway hyper-reactivity in rodents is mediated by the sphingosine-1-phosphate type 3 receptor.
    Trifilieff A, Fozard JR.
    J Pharmacol Exp Ther; 2012 Aug 15; 342(2):399-406. PubMed ID: 22570366
    [Abstract] [Full Text] [Related]

  • 9. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.
    Brinkmann V.
    Pharmacol Ther; 2007 Jul 15; 115(1):84-105. PubMed ID: 17561264
    [Abstract] [Full Text] [Related]

  • 10. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.
    LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T, Probst B, Butler J, Wood A, Liau G, Billy E, Theuer A, Hla T, Wood J.
    Cancer Res; 2006 Jan 01; 66(1):221-31. PubMed ID: 16397235
    [Abstract] [Full Text] [Related]

  • 11. FTY720 inhibits S1P-mediated endothelial healing: relationship to S1P1-receptor surface expression.
    Krump-Konvalinkova V, Chwalla I, Siess W.
    Biochem Biophys Res Commun; 2008 Jun 13; 370(4):603-8. PubMed ID: 18402775
    [Abstract] [Full Text] [Related]

  • 12. Attenuation of cell motility observed with high doses of sphingosine 1-phosphate or phosphorylated FTY720 involves RGS2 through its interactions with the receptor S1P.
    Kohno T, Igarashi Y.
    Genes Cells; 2008 Jul 13; 13(7):747-57. PubMed ID: 18513330
    [Abstract] [Full Text] [Related]

  • 13. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
    Chiba K.
    Pharmacol Ther; 2005 Dec 13; 108(3):308-19. PubMed ID: 15951022
    [Abstract] [Full Text] [Related]

  • 14. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes.
    Forrest M, Sun SY, Hajdu R, Bergstrom J, Card D, Doherty G, Hale J, Keohane C, Meyers C, Milligan J, Mills S, Nomura N, Rosen H, Rosenbach M, Shei GJ, Singer II, Tian M, West S, White V, Xie J, Proia RL, Mandala S.
    J Pharmacol Exp Ther; 2004 May 13; 309(2):758-68. PubMed ID: 14747617
    [Abstract] [Full Text] [Related]

  • 15. Selective activation of G alpha i mediated signalling of S1P3 by FTY720-phosphate.
    Sensken SC, Stäubert C, Keul P, Levkau B, Schöneberg T, Gräler MH.
    Cell Signal; 2008 Jun 13; 20(6):1125-33. PubMed ID: 18313900
    [Abstract] [Full Text] [Related]

  • 16. Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells.
    Butler J, Lana D, Round O, LaMontagne K.
    Prostaglandins Other Lipid Mediat; 2004 Jan 13; 73(1-2):29-45. PubMed ID: 15165029
    [Abstract] [Full Text] [Related]

  • 17. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor.
    Walter DH, Rochwalsky U, Reinhold J, Seeger F, Aicher A, Urbich C, Spyridopoulos I, Chun J, Brinkmann V, Keul P, Levkau B, Zeiher AM, Dimmeler S, Haendeler J.
    Arterioscler Thromb Vasc Biol; 2007 Feb 13; 27(2):275-82. PubMed ID: 17158356
    [Abstract] [Full Text] [Related]

  • 18. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors.
    Gräler MH, Goetzl EJ.
    FASEB J; 2004 Mar 13; 18(3):551-3. PubMed ID: 14715694
    [Abstract] [Full Text] [Related]

  • 19. Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist.
    Murakami A, Takasugi H, Ohnuma S, Koide Y, Sakurai A, Takeda S, Hasegawa T, Sasamori J, Konno T, Hayashi K, Watanabe Y, Mori K, Sato Y, Takahashi A, Mochizuki N, Takakura N.
    Mol Pharmacol; 2010 Apr 13; 77(4):704-13. PubMed ID: 20097776
    [Abstract] [Full Text] [Related]

  • 20. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
    Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, Hoyer D, Mir A.
    Pharmacol Ther; 2008 Jan 13; 117(1):77-93. PubMed ID: 17961662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.